.png?width=400&height=111&name=Group%20(14).png)
Findings from a real-world smartphone data collection study reaffirm UCB’s commitment to delivering pioneering, tailored care solutions for individuals living with gMG
Learn more about our work with UCB. Beyond demonstrating that decentralized, smartphone-based methods to collect real-world data from gMG patients are feasible and may provide enhanced visibility into the burden of the disease, the study also identified unique clusters of exacerbation subtypes with specific symptom representation.
Smart Omix and Maternal Health
SVP of Product and Innovation, Francesca Rinaldo, MD PhD, talks about how Smart Omix can make an impact in confronting maternal health disparities.
From ‘Nice-to-Have to ‘Need-to-Have
VP of Strategy and Operations, Zeenia Framroze, writes about the paradigm-shifting trends of participant-centricity and rich real-world data for HIT Consultant.
Developing objective symptom measures with UCB Biopharma
doc.ai, now, a Sharecare company, an enterprise AI platform accelerating digital transformation in healthcare, and UCB, a multinational biopharma company headquartered in Brussels, Belgium, today announced a new collaboration in AI medical research with the launch of a digital health trial for myasthenia gravis, a neuromuscular disease that can lead to impaired speech, blurred vision, difficulty swallowing, and other symptoms.
The right tech can add real-world context to clinical trials.
SVP of Clinical Product and Innovation, Dr. Francesca Rinaldo, speaks to Outsourcing Pharma about how Smart Omix can provide researchers with the tools to unlock the potential of decentralized real-world clinical research. Conducting trials in a decentralized manner will no longer be a "nice to have" but a "need to have."